BLCO Stock Forecast & Price Target

Bausch & Lomb has raised its 2025 revenue guidance to a range of $5,050-$5,150 million, indicating a constant currency growth of 5-7%, which reflects strong operational momentum. The company also anticipates an increase in adjusted EBITDA to $860-$910 million, up from previous guidance of $850-$900 million, highlighting improved profitability. Additionally, the robust performance of products such as MIEBO, which exhibits a remarkable 111% year-over-year prescription growth, and XIIDRA, which has achieved $82 million in sales with a 12% year-over-year increase in prescriptions, further strengthens the outlook for the company.

Bausch & Lomb experienced revenue growth in two of its segments in 2Q25, with Vision Care revenue reaching $753 million (up 8% YoY) and Surgical revenue at $216 million (up 3% YoY), while Pharmaceuticals revenue fell slightly to $309 million, just below the previous year's figure. Significant risks include pricing pressure on key products like XIIDRA, potential difficulties in developing and acquiring new products, and volatility from emerging markets and foreign exchange rates. Additionally, projections indicate a concerning net debt level of $13.25 per share and an overall outlook clouded by risks of lower-than-expected product uptake and potential dilution.